drugset / Trial / NCT00158847

Summary

The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.

Timeline

Start
2000-04
Primary completion
—
Completion
2005-05

Outcome

Met primary endpoint

paper Fluticasone therapy decreased counts of mucosal CD3(+) cells (-55% [95% CI, -74% to -22%]; P = 0.004) PMID 19841453 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 0.5 mg Inhaled
Subject Salmeterol Other / unclassified 0.05 mg Inhaled